Cite
Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl-xL inhibitor.
MLA
Swiecicki, Paul L., et al. “Randomized Trial of Laryngeal Organ Preservation Evaluating Two Cycles of Induction Chemotherapy with Platinum, Docetaxel, and a Novel Bcl-XL Inhibitor.” Head & Neck, vol. 44, no. 7, July 2022, pp. 1509–19. EBSCOhost, https://doi.org/10.1002/hed.27043.
APA
Swiecicki, P. L., Bellile, E., Casper, K., Chinn, S. B., Dragovic, A. F., Jolly, S., Kupfer, R., Malloy, K. M., Mierzwa, M. L., Shuman, A. G., Spector, M. E., Srinivasan, A., Stucken, C., Bradford, C. R., Eisbruch, A., Carey, T. E., Prince, M. E., Wolf, G. T., & Worden, F. P. (2022). Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl-xL inhibitor. Head & Neck, 44(7), 1509–1519. https://doi.org/10.1002/hed.27043
Chicago
Swiecicki, Paul L, Emily Bellile, Keith Casper, Steven Bennett Chinn, Aleksandar F Dragovic, Shruti Jolly, Robbi Kupfer, et al. 2022. “Randomized Trial of Laryngeal Organ Preservation Evaluating Two Cycles of Induction Chemotherapy with Platinum, Docetaxel, and a Novel Bcl-XL Inhibitor.” Head & Neck 44 (7): 1509–19. doi:10.1002/hed.27043.